{"filing":{"accession_number":"0001213900-26-065845","cik":"0000906709","ticker":"NKTR","company_name":"NEKTAR THERAPEUTICS","form":"8-K","filing_date":"2026-06-05","report_date":null,"primary_document":"ea0293744-8k_nektar.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/906709/000121390026065845/ea0293744-8k_nektar.htm"},"events":[{"id":6553,"run_id":5736,"accession_number":"0001213900-26-065845","anchor_item_number":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The filing discloses results of Nektar Therapeutics' Annual Meeting of Stockholders held on June 4, 2026, under Item 5.07. Four proposals were voted on: election of director Howard W. Robin (13,164,879 for, 4,975,288 against), approval of a 3,000,000 share increase to the 2017 Performance Incentive Plan (13,160,661 for, 4,902,925 against), ratification of Ernst \u0026 Young LLP as auditor (22,591,556 for, 118,592 against), and approval of executive compensation (18,154,226 for, 161,005 against). All proposals passed with substantial majorities, making this a standard shareholder vote results disclosure.","company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","filing_date":"2026-06-05","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":4864,"accession_number":"0001213900-26-065845","item_number":null,"item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses results of Nektar Therapeutics' Annual Meeting of Stockholders held on June 4, 2026, under Item 5.07. Four proposals were voted on: election of director Howard W. Robin (13,164,879 for, 4,975,288 against), approval of a 3,000,000 share increase to the 2017 Performance Incentive Plan (13,160,661 for, 4,902,925 against), ratification of Ernst \u0026 Young LLP as auditor (22,591,556 for, 118,592 against), and approval of executive compensation (18,154,226 for, 161,005 against). All proposals passed with substantial majorities, making this a standard shareholder vote results disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T20:31:23.516405+00:00","company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","filing_date":"2026-06-05"}]}